The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Imatinib Rowex 400mg Film-coated tablets

Rowex LtdPA0711/248/002

Main Information

Trade NameImatinib Rowex 400mg Film-coated tablets
Active SubstancesImatinib mesilate
Dosage FormFilm-coated tablet
Licence HolderRowex Ltd
Licence NumberPA0711/248/002

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE01 imatinib


License statusAuthorised
Licence Issued04/12/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back